{"id":"76cbc9a5-8f6d-42be-916f-88344289b6ef","name":"BrainQ","slug":"brainq","description":"BrainQ is an Israeli neurotechnology company developing AI-powered, non-invasive electromagnetic therapy for stroke recovery. Its [BrainQ BCI](/models/brainq-non-invasive-bci) device delivers frequency-tuned electromagnetic stimulation to enhance brain recovery after ischemic stroke. The EMAGINE pivotal trial is enrolling 150 patients across 20 US clinical sites.","status":null,"founded":null,"hq":"Israel","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"brainqtech.com","fundingTotal":null,"type":"both","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://brainqtech.com/","title":"BRAIN.Q: AI-Powered Noninvasive Solution for Stroke Recovery","sourceName":"BrainQ"}],"keyFacts":[{"label":"FDA","value":"Breakthrough Device Designation"},{"label":"Type","value":"Non-invasive electromagnetic"},{"label":"Indication","value":"Stroke recovery"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:32:37.870Z","updatedAt":"2026-08-08T22:39:07.258Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/brainq","url":"https://registry.deploy.report/companies/brainq","name":"BrainQ","description":"BrainQ is an Israeli neurotechnology company developing AI-powered, non-invasive electromagnetic therapy for stroke recovery. Its [BrainQ BCI](/models/brainq-non-invasive-bci) device delivers frequency-tuned electromagnetic stimulation to enhance brain recovery after ischemic stroke. The EMAGINE pivotal trial is enrolling 150 patients across 20 US clinical sites.","identifier":"76cbc9a5-8f6d-42be-916f-88344289b6ef","address":"Israel","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}